MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours

5th May 2026 Uncategorised 0

Study expands evaluation of survivin‑targeting vaccine

More: MimiVax and Roswell Park open phase 2 trial of SurVaxM for metastatic neuroendocrine tumours
Source: News